See All Slides - tctmd.com

Slides

Presentation TCT 2012

When Should MVD be Managed Medically?

Presenter: William Boden

October 23, 2012

Presentation TCT 2012

Autologous Cardiac Stem Cells in VAD Patients

Presenter: Robert Michler

October 23, 2012

Presentation TCT 2012

TCT-34. ABSORB EXTEND: An Interim Report on the 12-month Clinical Outcomes from the First 250 Patients Enrolled

Presenter: Antonio Bartorelli

October 23, 2012

Presentation TCT 2012

HFPEF: Overview of Pathophysiology and Therapies

Presenter: William Little

October 23, 2012

Presentation TCT 2012

Surgical Perspectives of the MitraClip and Its Role in the Treatment of Severe Degenerative and Functional MR

Presenter: Hendrik Treede

October 23, 2012

Presentation TCT 2012

Pathogenesis of Vulnerable Plaque 2012: What's New?

Presenter: Renu Virmani

October 23, 2012

Presentation TCT 2012

Selection of Angioplasty Guiding Catheters, Wires, and Balloons

Presenter: Aaron Kugelmass

October 23, 2012

Presentation TCT 2012

TCT-38. Two-year Clinical Data of Cohort 1 and Multi-modality Imaging Results Up to 1-year Follow-up of the BIOSOLVE-I Study with the Paclitaxel-eluting Bioabsorbable...

Presenter: Michael Haude

October 23, 2012

Presentation TCT 2012

Attributes of the Perfect LAA Closure Device: What All the Companies Should Strive For

Presenter: Horst Sievert

October 23, 2012

Presentation TCT 2012

Debate II. Is Straight-Line Flow to the Foot Sufficient (And Is the Angiosome Concept Nonsense)? Con!

Presenter: Andrej Schmidt

October 23, 2012

Advertisement

Slides

When Should MVD be Managed Medically?

Autologous Cardiac Stem Cells in VAD Patients

TCT-34. ABSORB EXTEND: An Interim Report on the 12-month Clinical Outcomes from the First 250 Patients Enrolled

HFPEF: Overview of Pathophysiology and Therapies

Surgical Perspectives of the MitraClip and Its Role in the Treatment of Severe Degenerative and Functional MR

Pathogenesis of Vulnerable Plaque 2012: What's New?

Selection of Angioplasty Guiding Catheters, Wires, and Balloons

TCT-38. Two-year Clinical Data of Cohort 1 and Multi-modality Imaging Results Up to 1-year Follow-up of the BIOSOLVE-I Study with the Paclitaxel-eluting Bioabsorbable...

Attributes of the Perfect LAA Closure Device: What All the Companies Should Strive For

Debate II. Is Straight-Line Flow to the Foot Sufficient (And Is the Angiosome Concept Nonsense)? Con!

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content